Rituximab and ocrelizumab go head to head in randomized trial ...

The US Food and Drug Administration (FDA) held a 2-day public hearing this week to solicit input about the marketing and use of medications and medical devices for off-label use. It is fairly common ...

Drugs like leucovorin are frequently used off-label because doctors believe that the benefits outweigh the risks. However, there is often limited awareness about these treatments, so they may go ...

Add Yahoo as a preferred source to see more of our stories on Google. When a clinician prescribes a medication for a purpose for which its not indicated by the U.S. Food and Drug Administration (FDA), ...

Health Care Cost Associated With Contemporary Chronic Myelogenous Leukemia Therapy Compared With That of Other Hematologic Malignancies In Japan, for pharmaceutical products to be covered by public ...

COLUMBUS, Ohio (WCMH) — A discussion about off-label drugs is back in the spotlight in Ohio after a similar effort failed last year. House Bill 12 would generally allow a doctor to prescribe any drug, ...

The US Food and Drug Administration (FDA) finalized guidance to industry on allowable communications to health care providers about off-label drug and device uses. The Q&A document, issued on 6 ...

The largest published prospective evaluation of off-label targeted cancer therapies has shown that more patients could benefit from existing drugs. After including over 1600 patients in the Dutch ...

DRUP is evaluating off-label use of anticancer drugs — the treatment of one cancer type with drugs approved for another — in people with advanced tumours who lacked alternative standard treatment ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

A new sociomedical perspective shows how off-label use of GLP-1 drugs for slimness is redefining what counts as a healthy, responsible body, revealing hidden moral pressures and global inequalities ...